Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2010

View Archived Issues

Merck & Co. claims new HIV integrase inhibitors

Novartis discovers new orexin receptor antagonists

Zydus-Cadila identifies new GPR119 receptor agonists

Miraculins launches ELISA kit to detect PSP94 in urine

CCR5 gene disruption by SB-728 in HSPCs may be new approach to treat HIV/AIDS

Health Canada conditionally approves Tasigna for CML

ISV-303 enters phase I/II trial for postsurgical ocular pain

Takepron approved for additional indication in Japan

Nesina in combination with thiazolidinediones approved in Japan for diabetes

Soligenix receives FDA grant to advance orBec in gastrointestinal GVHD

FCGR2B gene variant is associated with protection from malaria

Daiichi Sankyo claims new ligands of voltage-gated calcium channel subunit alpha2/delta

Baxter acquires exclusive commercial rights to Glassia in U.S. and other countries

Banyu Pharma and Merck & Co. present new PKB inhibitors

Amgen reports pipeline update for second quarter 2010

WHO grants prequalification status to Pfizer's Prevenar 13

Gruenenthal discloses new bradykinin B1 receptor antagonists

Bristol-Myers Squibb offers pipeline update for Q2 2010

Hepatitis E vaccine HEV-239 is safe in phase III trial in healthy adults

AstraZeneca presents new inhibitors of GlyT-1

Perampanel shows promise in phase III trial in epilepsy

Medivir partners with Daewoong to distribute Xerclear in South Korea

Sunitinib/erlotinib improves progression-free survival in NSCLC

Synthetic calcium phosphate ceramics induce osteogenesis in preclinical study

FDA grants orphan drug status for brain cancer product 2B3-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...